HTT RESEARCH, DEVELOPMENT, OPTION AND LICENSE AGREEMENT AMONG ISIS PHARMACEUTICALS, INC., AND AND HOFFMANN-LA ROCHE INC.License Agreement • August 6th, 2013 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • California
This HTT RESEARCH, DEVELOPMENT, OPTION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of the 8th day of April, 2013 (the “Effective Date”) by and among ISIS PHARMACEUTICALS, INC., a Delaware corporation, having its principal place of business at 2855 Gazelle Court, Carlsbad, California 92010 (“Isis”), and F. HOFFMANN-LA ROCHE LTD, a Swiss corporation, having its principal place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche Basel”) and HOFFMANN-LA ROCHE INC., a New Jersey corporation, having its principal place of business at 340 Kingsland Street, Nutley, New Jersey 07110 (“Roche Nutley”; Roche Basel and Roche Nutley are collectively referred to as “Roche”). Roche and Isis each may be referred to herein individually as a “Party” or collectively as the “Parties.” Capitalized terms used in this Agreement, whether used in the singular or the plural, have the meaning set forth in APPENDIX 1. All attached appendices and schedules are a part of this Agreeme
Re: Research Agreement dated August 10, 2011 (the “Agreement”) between Isis Pharmaceuticals, Inc. (“Isis”) and CHDI Foundation, Inc. (the “Foundation”)Isis Pharmaceuticals Inc • August 6th, 2013 • Pharmaceutical preparations
This letter agreement serves to confirm certain additional agreements between Isis and the Foundation related to the Agreement and the subject matter thereof.
